ReviewLiver cancer2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
Open access · goldAbstract readReview
In one paragraph
Review in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Extracellular matrix polysaccharides and glycoproteins in ovarian cancer: structural-functional macromolecular perspectives and potential exosome-derived biomarkers.Cell communication and signaling : CCS · 2026Review
- Article
- Mechanisms of ferroptosis in primary hepatocellular carcinoma and progress of artificial intelligence-based predictive modeling in hepatocellular carcinoma.World journal of gastroenterology · 2025Review
- FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.European journal of medical research · 2025Article
- Where the hope grows: strategies to fight cancer in China.Science China. Life sciences · 2025Article
- Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway.Immunity, inflammation and disease · 2025Article
- Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).Liver cancer · 2025Review
- Lysionotin promoted apoptosis of hepatocellular carcinoma cells via inducing autophagy.Discover oncology · 2025Article
- Copper-mediated SEC14L3 promotes cuproptosis to inhibit hepatocellular carcinoma growth via ERK/YY1/FDX1 axis.Communications biology · 2025Article
- Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study.Frontiers in pharmacology · 2025Article
- Trends in liver cancer burden in China and G20: a comparative analysis using GBD 2021.Frontiers in oncology · 2025Article
- Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score.Frontiers in surgery · 2025Article
- Repurposing Artemisinin-Based Drugs from Antimalarial to Pan-Therapeutic: Pharmacological Promise and Therapeutic Challenges.Drug design, development and therapy · 2025Review
- Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection.Frontiers in pharmacology · 2025Article
- Relationships Among Serological Indicators andCombinatorial chemistry & high throughput screening · 2025Article
- The Role of Cisplatin Prodrugs Bonded to Polymer Carriers for Nanodrug-targeted Treatment ofAnti-cancer agents in medicinal chemistry · 2025Article
- Comprehensive Analysis of the Role of Heat Shock Proteins in the Immune Microenvironment and Clinical Significance of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors at 20 institutions in 2 countries.
Yongkun SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wen ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xinyu BiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhengqiang YangDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yu TangDepartment of GCP Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Liming JiangDepartment of Diagnostic Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Feng BiDepartment of Medical Oncology, West China Hospital, Chengdu, China.
Minshan ChenDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shuqun ChengThe Six Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Yihebali ChiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue HanDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing HuangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhen HuangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, China.
Liqun JiaDepartment of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Zhichao JiangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing JinDepartment of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhengyu JinDepartment of Radiology, Peking Union Medical College Hospital, Beijing, China.
Xiao LiDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhiyu LiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Medical Oncology, Peking University International Hospital, Beijing, China.
Lianxin LiuDepartment of Hepatic Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Yunpeng LiuDepartment of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yinying LuDepartment of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Shichun LuDepartment of Hepatobiliary Surgery, First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Chinese PLA Medical School, Beijing, China.
Qinghua MengDepartment of Clinical Care Medicine of Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zuoxing NiuDepartment of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
Hongming PanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Shukui QinDepartment of Medical Oncology, PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China.
Wang QuDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Guoliang ShaoDepartment of Interventional Radiology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Feng ShenDepartment of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Tianqiang SongDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yan SongDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Aiping TianDepartment of Traditional Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianhua WangDepartment of Interventional Radiology, Zhongshan Hospital Fudan University, Shanghai, China.
Wenling WangDepartment of Radiology, The Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, China.
Zhe WangDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Liqun WuDepartment of Hepatic Biliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Feng XiaDepartment of Hepatobiliary Surgery, The Southwest Hospital of AMU, Chongqing, China.
Baocai XingDepartment of Hepatobiliary and Pancreatic Surgery Unit I, Beijing Cancer Hospital, Beijing, China.
Jianming XuDepartment of Gastrointestinal Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Huadan XueDepartment of Radiology, Peking Union Medical College Hospital, Beijing, China.
Dong YanDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lin YangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianming YingDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jingping YunDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhaochong ZengDepartment of Radiology, Zhongshan Hospital Fudan University, Shanghai, China.
Xuewen ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, China.
Yanqiao ZhangDepartment of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yefan ZhangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianjun ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianguo ZhouDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xu ZhuDepartment of Interventional Radiology, Beijing Cancer Hospital, Beijing, China.
Yinghua ZouDepartment of Interventional Radiology, Peking University First Hospital, Beijing, China.
Jiahong DongDepartment of Hepatopancreatobiliary Surgery, Beijing Tsinghua Changgung Hospital, Beijing, China.
Jia FanDepartment of Liver Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Wan Yee LauDepartment of Hepatic Biliary Pancreatic Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Yan SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jinming YuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Taian, China.
Hong ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Aiping ZhouDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNSun Yat-sen University · CNPeking University · CNChinese PLA General Hospital · CNHarbin Medical University · CNSecond Military Medical University · CNShandong Tumor Hospital · CNXijing Hospital · CN81th Hospital of PLA · CNBeijing Tsinghua Chang Gung Hospital · CNCancer Hospital of Chinese Academy of Medical Sciences · CNCapital Medical University · CNChina-Japan Friendship Hospital · CNChinese University of Hong Kong · HKFirst Hospital of China Medical University · CNFudan University · CNGuiyang Medical University · CNQingdao University · CNSecond Affiliated Hospital of Jilin University · CNSir Run Run Shaw Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
Indexed as
Chinese interdisciplinary expertsConsensusHepatocellular carcinomaMolecular targeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.